Co-Authors
This is a "connection" page, showing publications co-authored by Hubert Schrezenmeier and Thomas Appl.
Connection Strength
0.296
-
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. Transfus Med Hemother. 2021 May; 48(3):137-147.
Score: 0.235
-
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021 10 15; 131(20).
Score: 0.061